Skip to Content


Treatment for Dry Eye

Inspire Continues Discussions with FDA on Dry Eye Program

DURHAM, N.C., October 5, 2006 - Inspire Pharmaceuticals, Inc. met with the U.S. Food and Drug Administration (FDA) in late September 2006 to continue ongoing discussions related to Inspire's dry eye clinical program for Prolacria (the proposed U.S. trade name for diquafosol tetrasodium ophthalmic solution 2%).

Based on this meeting, Inspire plans to provide the FDA with additional information to facilitate ongoing discussions related to Prolacria. Inspire expects to meet with the FDA again following the FDA's review of this information.

Christy L. Shaffer, Ph.D., President and CEO of Inspire, stated, "We believe our discussions with the FDA have been constructive but the overall program remains challenging and the outcome is uncertain."

Source: Inspire Pharmaceuticals, Inc.

Posted: October 2006

Related Articles

Prolacria (diquafosol tetrasodium) FDA Approval History